Table 1.
Baseline characteristics.
| Baseline Characteristics | Resected Primary Tumor |
|||
|---|---|---|---|---|
| No (n = 486) | Yes (n = 513) | Total (n = 999) | p-Value | |
| Age (years) | 0.7309 1 | |||
| N | 486 | 513 | 999 | |
| Mean (SD) | 59.0 (9.4) | 58.7 (9.9) | 58.8 (9.7) | |
| Median | 60.0 | 60.0 | 60.0 | |
| Range | 33.0, 75.0 | 29.0, 75.0 | 29.0, 75.0 | |
| Age, n (%) | 0.9412 2 | |||
| <70 years | 417 (85.8%) | 441 (86.0%) | 858 (85.9%) | |
| ≥70 years | 69 (14.2%) | 72 (14.0%) | 141 (14.1%) | |
| Treatment arm, n (%) | 0.8267 2 | |||
| Doublets CT + bevacizumab | 242 (49.8%) | 259 (50.5%) | 501 (50.2%) | |
| FOLFOXIRI + bevacizumab | 244 (50.2%) | 254 (49.5%) | 498 (49.8%) | |
| Gender, n (%) | 0.0087 2 | |||
| Female | 181 (37.2%) | 233 (45.4%) | 414 (41.4%) | |
| Male | 305 (62.8%) | 280 (54.6%) | 585 (58.6%) | |
| ECOG PS, n (%) | 0.0821 2 | |||
| 0 | 413 (85.0%) | 455 (88.7%) | 868 (86.9%) | |
| 1–2 | 73 (15.0%) | 58 (11.3%) | 131 (13.1%) | |
| Site of primary tumor, n (%) | <0.001 2 | |||
| Left rectum | 325 (69.4%) | 292 (57.4%) | 617 (63.2%) | |
| Right rectum | 143 (30.6%) | 217 (42.6%) | 360 (36.8%) | |
| Missing | 18 | 4 | 22 | |
| RAS/BRAF mutational status, n (%) | 0.007 2 | |||
| BRAF mutated | 25 (6.4%) | 59 (12.8%) | 84 (9.8%) | |
| RAS mutated | 275 (70.0%) | 301 (65.4%) | 576 (67.5%) | |
| RAS/BRAF wild type | 93 (23.7%) | 100 (21.7%) | 193 (22.6%) | |
| Missing | 93 | 53 | 146 | |
| Number of metastatic sites, n (%) | <0.001 2 | |||
| 1 | 136 (28.1%) | 216 (42.1%) | 352 (35.3%) | |
| >1 | 348 (71.9%) | 297 (57.9%) | 645 (64.7%) | |
| Missing | 2 | 0 | 2 | |
| Liver-only disease, n (%) | <0.001 2 | |||
| No | 379 (78.3%) | 342 (66.7%) | 721 (72.3%) | |
| Yes | 105 (21.7%) | 171 (33.3%) | 276 (27.7%) | |
| Missing | 2 | 0 | 2 | |
1 Kruskal–Wallis p-value; 2 chi-square p-value. CT: chemotherapy; ECOG PS: Eastern Cooperative Oncology Group Performance Status.